Daniela Santiesteban - Salarius Pharmaceuticals Director Program
| SLRX Stock | USD 1.52 0.15 10.95% |
Insider
Daniela Santiesteban is Director Program of Salarius Pharmaceuticals
| Address | 2450 Holcombe Boulevard, Houston, TX, United States, 77021 |
| Phone | 832 834 9144 |
| Web | https://www.salariuspharma.com |
Salarius Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5399) % which means that it has lost $0.5399 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1983) %, meaning that it created substantial loss on money invested by shareholders. Salarius Pharmaceuticals' management efficiency ratios could be used to measure how well Salarius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.002 in 2024. Return On Capital Employed is likely to drop to -0.0026 in 2024. At this time, Salarius Pharmaceuticals' Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2024, whereas Total Assets are likely to drop slightly above 6.3 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Lewicki | Mereo BioPharma Group | 72 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| McKee MD | GeoVax Labs | 72 | |
| Christine Rothe | Pieris Pharmaceuticals | N/A | |
| Pr Little | Affimed NV | N/A | |
| Torsten Hombeck | Akari Therapeutics PLC | 54 | |
| Steven Reich | Artelo Biosciences | 78 | |
| Denise Mueller | Affimed NV | 54 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| Andreas MD | Affimed NV | 63 | |
| Elizabeth Evans | Vaccinex | 51 | |
| Gordon MD | Pieris Pharmaceuticals | N/A | |
| Richard MD | Corvus Pharmaceuticals | 73 | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Gerald Goodman | Nutriband | 76 | |
| Melissa BradfordKlug | Akari Therapeutics PLC | 54 | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| MBBS MD | Mereo BioPharma Group | 54 | |
| Alan Esq | Corvus Pharmaceuticals | N/A | |
| Gregory MBA | Artelo Biosciences | 61 | |
| Annie Mack | Akari Therapeutics PLC | N/A | |
Management Performance
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.54 |
Salarius Pharmaceuticals Leadership Team
Elected by the shareholders, the Salarius Pharmaceuticals' board of directors comprises two types of representatives: Salarius Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Salarius. The board's role is to monitor Salarius Pharmaceuticals' management team and ensure that shareholders' interests are well served. Salarius Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Salarius Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark CPA, Executive CFO | ||
| Daniela Santiesteban, Director Program | ||
| David MBA, President CEO | ||
| MPH MD, Senior Development |
Salarius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Salarius Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | (764.62 K) | ||||
| Shares Outstanding | 1.44 M | ||||
| Shares Owned By Insiders | 2.52 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 65.04 K | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 18.12 X | ||||
| Gross Profit | (15.84 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Salarius Stock Analysis
When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.